Preclinical Evaluation of NKX019, a CD19-targeting CAR NK Cell

Time: 12:20 pm
day: Day Two


  • NKX019 is a highly potent CD19-directed CAR NK cell therapy with specific cytotoxic activity against CD19+ B-ALL tumors
  • NKX019 displays enhanced in vitro expansion and longer in vivo half-life than non-engineered NK cells
  • NKX019 exhibits advantages compared to CAR19+ T cells including faster cytotoxic kinetics and limited production of cytokines associated with CRS